chufangao/CTO huggingface dataset:
Clinical trial NCT04973449: Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
Official title: A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2
Acronym: AZD2816
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 2843.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-06-27
Primary completion date: 2022-02-04
Completion date: 2022-08-02
Baseline population: Full analysis set included all randomised participants who received study treatment, irrespective of their protocol adherence and continued participation in the study. Participants were analysed according to their randomised treatment assignment, irrespective of the treatment actually received.
Limitations and caveats: Since different assays were used between strains and also within the same strains between this study and historical control study D8110C00001 (NCT04516746), spike protein binding antibody results were summarised descriptively; no comparative analyses were conducted.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure~URL:~https://astrazenecagroup-dt.pharmacm.com/DT/Home
Clinical trial NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Official title: A Multi-center, Open-Label，Dose Escalation and Dose Expansion Phase I Study of HRS2300 Monotherapy or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor R\&D strategy adjustment
Enrollment: 13.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-10-25
Primary completion date: 2023-02-24
Completion date: 2023-05-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03107780: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Official title: Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Other - Aministrative hold
Enrollment: 86.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2018-07-09
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Clinical trial NCT04080505: Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?
Official title: Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-10
Primary completion date: 2023-03-03
Completion date: 2023-03-03
Clinical trial NCT02255097: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Official title: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 172.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-10-24
Primary completion date: 2016-04-22
Completion date: 2021-06-18
Baseline population: The baseline population included all participants allocated to receive ≥1 dose of pembrolizumab.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04163016: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Official title: A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Acronym: CHERISH
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-19
Primary completion date: 2023-05-23
Completion date: 2023-05-23
Baseline population: Baseline Characteristics refer to the Enrolled Set (ES) which consisted of all study participants who were confirmed as having signed the Informed Consent Form (ICF) to participate in the study and had provided the first blood sample. Due to data protection/data privacy, data cannot be reported for a single participant enrolled in 'Not Dosed' and 'CZP 400 mg Q2W' arms.
Plan to share individual participant data: NO
IPD sharing description: Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
Clinical trial NCT05838703: Tiotropium Handihaler vs. Tiotropium Respimat in COPD
Official title: Comparing the Acute Effects of Tiotropium Handihaler With Tiotropium Respimat on the Ventilation Distribution in COPD Patients
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study halted prematurely due to funding, prior to enrollment of first participant
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-01
Primary completion date: 2024-05-01
Completion date: 2024-05-01
Clinical trial NCT04405570: Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
Official title: A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19
Sponsor: Ridgeback Biotherapeutics, LP (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 204.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-06-19
Primary completion date: 2021-02-21
Completion date: 2021-02-21
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available.
Clinical trial NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies
Official title: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Administratively Complete
Enrollment: 221.0 (ACTUAL)
Number of arms: 15.0
Start date: 2015-06-26
Primary completion date: 2024-09-16
Completion date: 2024-09-16
Clinical trial NCT05695378: Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy
Sponsor: Kainos Medicine Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study
Enrollment: 68.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-02-27
Primary completion date: 2024-08-19
Completion date: 2024-08-19
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03606174: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Official title: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Sponsor: Mirati Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.
Enrollment: 260.0 (ACTUAL)
Number of arms: 9.0
Start date: 2018-09-11
Primary completion date: 2022-08-03
Completion date: 2022-08-22
Baseline population: Measured in the safety population, which included all participants who received ≥ 1 dose of any study treatment (sitravatinib, nivolumab, pembrolizumab, or enfortumab vedotin).
Plan to share individual participant data: NO
Clinical trial NCT04661579: Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
Official title: A Phase 2b Randomized, Open-label, Controlled, Single Center Study in Plasmodium Falciparum-infected and Uninfected Adults Age 18-55 Years Old in Kenya to Evaluate the Efficacy of the Delayed, Fractional Dose RTS,S/AS01E Malaria Vaccine in Subjects Treated With Artemisinin Combination Therapy Plus Primaquine
Sponsor: PATH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 620.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-11-06
Primary completion date: 2022-06-22
Completion date: 2022-08-17
Baseline population: The total vaccinated cohort (TVC) includes all randomized participants who received at least one vaccination.
Plan to share individual participant data: NO
Clinical trial NCT01433497: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Official title: A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Sponsor: AB Science (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 656.0 (ACTUAL)
Number of arms: 4.0
Start date: 2011-08-31
Primary completion date: 2019-09-30
Completion date: 2020-02-29
Clinical trial NCT04411641: Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Official title: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Acronym: HERCULES
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1131.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-24
Primary completion date: 2024-08-29
Completion date: 2024-08-29
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03877692: Acute Control of Chronic Hypertension
Official title: Acute Control of Chronic Hypertension in Preeclampsia
Acronym: ACCTIVE
Sponsor: Albany Medical College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-18
Primary completion date: 2020-07-20
Completion date: 2020-07-20
Plan to share individual participant data: NO
Clinical trial NCT03038009: Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
Official title: Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
Acronym: DACAB-GI-2
Sponsor: Ruijin Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: A new registration has been submitted due to a redesign of the study protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-31
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT04093505: Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
Official title: Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Intensive Postremission Therapy Double Blinded With or Without Glasdegib in Older Patients With Newly Diagnosed AML
Acronym: GnG
Sponsor: University Hospital Heidelberg (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study turned out no longer feasible. End of Recruitment: 25.5.2022
Enrollment: 28.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-04-01
Primary completion date: 2022-06-15
Completion date: 2022-06-23
Plan to share individual participant data: NO
Clinical trial NCT06276556: Extension Study of ABP-671 in Participants With Gout
Official title: A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301
Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Redesign of clinical development program for ABP-671: A new long-term safety study after the completion and analysis of Part 1 of ABP-671-301 (NCT05818085) is planned and will be conducted using the doses selected for the pivotal studies.
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-04-22
Primary completion date: 2024-09-05
Completion date: 2024-09-05
Plan to share individual participant data: NO
Clinical trial NCT04410978: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Official title: A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Acronym: GEMINI 1
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 974.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2024-07-15
Completion date: 2024-07-15
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03598036: Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Official title: An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis
Acronym: AURONA™
Sponsor: Aurinia Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment rate
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-21
Primary completion date: 2020-05-19
Completion date: 2020-05-19
Baseline population: Trial ended prematurely before any patients were enrolled into Cohort 2
Limitations and caveats: Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial.
Plan to share individual participant data: NO
Clinical trial NCT04327700: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Official title: A Phase II Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib as Second-line Therapy For Patients With Advanced Hepatocellular Carcinoma.
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accruals
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-26
Primary completion date: 2024-05-31
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT05655299: VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
Acronym: Serenity PsO
Sponsor: Ventyx Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 222.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-11-17
Primary completion date: 2023-09-25
Completion date: 2023-12-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04335305: Checkpoint Blockade in COVID-19 Pandemic
Official title: A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia
Acronym: COPERNICO
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruitment issues
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-09
Primary completion date: 2021-03-08
Completion date: 2021-06-21
Clinical trial NCT03747562: Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients.
Official title: Multi-centre, Double-blind, Randomized-controlled Trial to Study the Efficacy and Safety of Gabapentin to Reduce Strong Opioid Use in Treatment of Radiation-induced Pain in Head and Neck Cancer Patients During Curative Radio(chemo)therapy.
Acronym: stREnGTH
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-01
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: NO
Clinical trial NCT03735875: Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Official title: A Phase Ib/II Study of Venetoclax in Combination With Quizartinib in FLT3-Mutated Acute Myelogenous Leukemia (AML)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-25
Primary completion date: 2023-07-26
Completion date: 2023-07-26
Baseline population: This study did not move on to the Phase II portion of the study.
Limitations and caveats: This study was terminated early due to competing trials. All participants in the Phase I portion of this study were treated at dose level 0, therefore there was only one treatment arm for this study. This study did not move on to the Phase II portion of the study. Therefore, no patients were accrued on the Phase II portion of the study.
Clinical trial NCT06064279: Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Official title: Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Acronym: HAITEN-ICI
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The funding for this trial was removed.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-06-04
Primary completion date: 2024-06-04
Completion date: 2024-06-04
Plan to share individual participant data: YES
Clinical trial NCT05523089: The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Official title: A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Assess the Prophylactic Antiviral Activity Against Influenza, Safety, Tolerability, and Pharmacokinetics of CD388 Via a Human Viral Challenge Model
Sponsor: Cidara Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 59.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-09-09
Primary completion date: 2023-07-17
Completion date: 2023-07-17
Baseline population: The Safety Population included all participants who received at least 1 dose of study intervention. Participants were analyzed according to the study intervention they received.
Plan to share individual participant data: NO
Clinical trial NCT05717400: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Official title: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI Request
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-07
Primary completion date: 2024-08-29
Completion date: 2024-08-29